IL-17A and TNF-α inhibitors induce multiple molecular changes in psoriasis

Adalimumab and secukinumab are commonly used for moderate to severe psoriasis vulgaris (PV). Although distinct individual responses to and impaired effectiveness of these biological agents occur occasionally, little is known about the underlying reasons. Here, we report a proteomic analysis of psori...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Qiang, Li, Dan, Xie, Bi Bo, Hu, Li Hua, Huang, Jia, Jia, Xiao Xiao, Tang, Yan Li, Liu, Gan Hong, Shen, Ning Ning, Yu, Xiao Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723344/
https://www.ncbi.nlm.nih.gov/pubmed/36483564
http://dx.doi.org/10.3389/fimmu.2022.1015182

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723344/
https://www.ncbi.nlm.nih.gov/pubmed/36483564
http://dx.doi.org/10.3389/fimmu.2022.1015182

Ejemplares similares